ELIZABETH BRIGHT: Open Payments
NPI 1770138000 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,080 in 50 payments from 12 companies in 2025. Trend: 2023 $1,699 · 2024 $801 · 2025 $1,080
Food & beverage: $1,076Education: $4
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 9 | $345 |
| Alkermes, Inc. | 15 | $185 |
| Neurocrine BioSciences, Inc. | 5 | $125 |
| Supernus Pharmaceuticals, Inc. | 4 | $118 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $85 |
| E.R. Squibb & Sons, L.L.C. | 2 | $44 |
| Collegium Pharmaceutical, Inc. | 2 | $42 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| ABBVIE INC. | 1 | $29 |
Products named: Auvelity, ARISTADA, INGREZZA, Qelbree, CAPLYTA, LYBALVI, COBENFY, Jornay PM.
Industry payments across LA — which companies pay providers there.
